Eplerenone: An underused medication?

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 15, Issue 4, 2010, Pages 318-325

  Abuannadi, Mohammad ^a   O'Keefe, James H ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

aldosterone antagonist; eplerenone; heart failure; hypertension; myocardial infarction

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANDROGEN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ATENOLOL; CHLORTALIDONE; CYCLOSPORIN; CYTOCHROME P450 3A4; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; ERYTHROMYCIN; FLUCONAZOLE; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYPERICUM PERFORATUM EXTRACT; KETOCONAZOLE; LOOP DIURETIC AGENT; LOSARTAN; PLACEBO; POTASSIUM; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; PROGESTERONE RECEPTOR; SAQUINAVIR; SPIRONOLACTONE; VERAPAMIL; ALDOSTERONE ANTAGONIST; DRUG DERIVATIVE;

ADD ON THERAPY; ALBUMINURIA; AREA UNDER THE CURVE; ARTERIAL STIFFNESS; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; GRAPEFRUIT JUICE; GYNECOMASTIA; HEART ARRHYTHMIA; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERICUM PERFORATUM; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; MASTALGIA; MENSTRUAL IRREGULARITY; MITOCHONDRIAL PERMEABILITY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT MONITORING; PATIENT SELECTION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR AFFINITY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; STEROID BINDING; SYSTOLIC BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HEART VENTRICLE REMODELING; RISK; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; CARDIOVASCULAR DISEASES; HEART FAILURE; HUMANS; HYPERKALEMIA; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIAL INFARCTION; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 78651312585     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248410371946     Document Type: Review

References (63)

1. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003 ; 348 (14). 1309-1321.
2. Pitt B., Zannad F., Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999 ; 341 (10). 709-717.
3. Pitt B., Reichek N., Willenbrock R., et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003 ; 108 (15). 1831-1838.
4. de Gasparo M., Joss U., Ramjoue HP, et al. Three new epoxyspirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987 ; 240 (2). 650-656.
5. Schersten B., Thulin T., Kuylenstierna J., et al. Clinical and biochemical effects of spironolactone administered once daily in primary hypertension. Multicenter Sweden study. Hypertension. 1980 ; 2 (5). 672-679.
6. Brown NJ Eplerenone: cardiovascular protection. Circulation. 2003 ; 107 (19). 2512-2518.
7. Sica DA Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev. 2005 ; 10 (1). 23-29.
8. Cook CS, Berry LM, Burton E. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica. 2004 ; 34 (3). 215-228.
9. Cook CS, Berry LM, Kim DH, Burton EG, Hribar JD, Zhang L. Involvement of CYP3A in the metabolism of eplerenone in humans and dogs: differential metabolism by CYP3A4 and CYP3A5. Drug Metab Dispos. 2002 ; 30 (12). 1344-1351.
10. Sigurdsson A., Held P., Swedberg K. Short- and long-term neurohormonal activation following acute myocardial infarction. Am Heart J. 1993 ; 126 (5). 1068-1076.
11. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol. 1992 ; 20 (1). 248-254.
12. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001 ; 345 (23). 1667-1675.
13. Cohn JN, Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991 ; 325 (5). 303-310.
14. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987 ; 316 (23). 1429-1435.
15. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991 ; 325 (5). 293-302.
16. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med. 1992 ; 327 (10). 685-691.
17. Pitt B. " Escape" of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther. 1995 ; 9 (1). 145-149.
18. Borghi C., Boschi S., Ambrosioni E., Melandri G., Branzi A., Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993 ; 33 (1). 40-45.
19. Gheorghiade M., Khan S., Blair JE, et al. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. Am Heart J. 2009 ; 158 (3). 437-443.
20. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005 ; 46 (3). 425-431.
21. Adamopoulos C., Ahmed A., Fay R., et al. Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial. Eur J Heart Fail. 2009 ; 11 (11). 1099-1105.
22. Weintraub WS, Zhang Z., Mahoney EM, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005 ; 111 (9). 1106-1113.
23. Zhang Z., Mahoney EM, Kolm P., et al. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ace inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs. 2010 ; 10 (1). 55-63.
24. Nct00232180. A comparison of outcomes in patients in New York Heart Association (NYHA) class II heart failure when treated with eplerenone or placebo in addition to standard heart failure medicines (EMPHASIS-HF). http://clinicaltrials.gov/ct2/show/study/NCT00232180. Accessed February 18, 2010.
25. Fraccarollo D., Galuppo P., Schraut S., et al. Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response. Hypertension. 2008 ; 51 (4). 905-914.
26. Enomoto S., Yoshiyama M., Omura T., et al. Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction. Heart. 2005 ; 91 (12). 1595-1600.
27. Schmidt K., Tissier R., Ghaleh B., Drogies T., Felix SB, Krieg T. Cardioprotective effects of mineralocorticoid receptor antagonists at reperfusion. Eur Heart J. DOI-10.1093/eurheartj/ehp555.
28. Chai W., Garrelds IM, de Vries R., Danser AH Cardioprotective effects of eplerenone in the rat heart: interaction with locally synthesized or blood-derived aldosterone ? Hypertension. 2006 ; 47 (4). 665-670.
29. Downey JM, Krieg T., Cohen MV Mapping preconditioning's signaling pathways: an engineering approach. Ann N Y Acad Sci. 2008 ; 1123: 187-196.
30. Iraqi W., Rossignol P., Angioi M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation. 2009 ; 119 (18). 2471-2479.
31. Weir RA, Mark PB, Petrie CJ, et al. Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect? Am Heart J. 2009 ; 157 (6). 1088-1096.
32. Mak GJ, Ledwidge MT, Watson CJ, et al. Natural history of markers of collagen turnover in patients with early diastolic dysfunction and impact of eplerenone. J Am Coll Cardiol. 2009 ; 54 (18). 1674-1682.
33. Young M., Funder JW Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology. 2004 ; 145 (7). 3153-3157.
34. Susic D., Varagic J., Ahn J., Matavelli L., Frohlich ED Long-term mineralocorticoid receptor blockade reduces fibrosis and improves cardiac performance and coronary hemodynamics in elderly SHR. Am J Physiol Heart Circ Physiol. 2007 ; 292 (1). H175 - H179.
35. Rocha R., Rudolph AE, Frierdich GE, et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002 ; 283 (5). H1802 - H1810.
36. Nagata K., Obata K., Xu J., et al. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension. 2006 ; 47 (4). 656-664.
37. Kuster GM, Kotlyar E., Rude MK, et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. 2005 ; 111 (4). 420-427.
38. Nct00094302. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (TOPCAT). http://clinicaltrials.gov/show/ NCT00094302. Accessed February 15, 2010.
39. Ma J., Stafford RS Screening, treatment, and control of hypertension in US private physician offices, 2003-2004. Hypertension. 2008 ; 51 (5). 1275-1281.
40. Multiple Risk Factor Intervention Trial investigators. Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial. Circulation. 1990 ; 82 (5). 1616-1628.
41. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991 ; 265 (24). 3255-3264.
42. ALLHAT Trial investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 ; 288 (23). 2981-2997.
43. Lesne M. Comparison of the pharmacokinetics and pharmacodynamics of torasemide and furosemide in healthy volunteers. Arzneimittelforschung. 1988 ; 38 (1A). 160-163.
44. Carter BL, Ernst ME, Cohen JD Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension. 2004 ; 43 (1). 4-9.
45. Sato A., Fukuda S. Clinical effects of eplerenone, a selective aldosterone blocker, in Japanese patients with essential hypertension. J Hum Hypertens. 2010 ; 24 (6). 387-394.
46. White WB, Carr AA, Krause S., Jordan R., Roniker B., Oigman W. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension. Am J Cardiol. 2003 ; 92 (1). 38-42.
47. Krum H., Nolly H., Workman D., et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002 ; 40 (2). 117-123.
48. Williams GH, Burgess E., Kolloch RE, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004 ; 93 (8). 990-996.
49. Weinberger MH, Roniker B., Krause SL, Weiss RJ Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002 ; 15 (8). 709-716.
50. White WB, Duprez D., St Hillaire R., et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003 ; 41 (5). 1021-1026.
51. Weinberger MH, White WB, Ruilope LM, et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J. 2005 ; 150 (3). 426-433.
52. Hollenberg NK, Williams GH, Anderson R., Akhras KS, Bittman RM, Krause SL Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension. Arch Intern Med. 2003 ; 163 (13). 1543-1548.
53. Mizuguchi Y., Ichihara A., Seki Y., et al. Renoprotective effects of mineralocorticoid receptor blockade in hemi-nephrectomized (pro)renin-receptor- transgenic rats. Clin Exp Pharmacol Physiol. 2010 ; 37 (5-6). 569-573.
54. Nishiyama A., Kobori H., Konishi Y., et al. Mineralocorticoid receptor blockade enhances the anti-proteinuric effect of an angiotensin II blocker through inhibiting podocyte injury in type 2 diabetic rats. J Pharmacol Exp Ther. 2010 ; 332 (2). 1072-1080.
55. Takai S., Jin D., Muramatsu M., Kirimura K., Sakonjo H., Miyazaki M. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension. 2005 ; 46 (5). 1135-1139.
56. Joffe HV, Kwong RY, Gerhard-Herman MD, Rice C., Feldman K., Adler GK Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. J Clin Endocrinol Metab. 2007 ; 92 (7). 2552-2558.
57. Savoia C., Touyz RM, Amiri F., Schiffrin EL Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008 ; 51 (2). 432-439.
58. Cachofeiro V., Miana M., de Las Heras N., et al. Aldosterone and the vascular system. J Steroid Biochem Mol Biol. 2008 ; 109 (3-5). 331-335.
59. Stewart RA, Kerr AJ, Cowan BR, et al. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis. Am Heart J. 2008 ; 156 (2). 348-355.
60. Pitt B., Bakris G., Ruilope LM, DiCarlo L., Mukherjee R. Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation. 2008 ; 118 (16). 1643-1650.
61. Schepkens H., Vanholder R., Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001 ; 110 (6). 438-441.
62. Burgess ED, Lacourciere Y., Ruilope-Urioste LM, et al. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension. Clin Ther. 2003 ; 25 (9). 2388-2404.
63. Jeunemaitre X., Chatellier G., Kreft- Jais C., et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987 ; 60 (10). 820-825.